Follicular lymphoma grade III, unspecified, lymph nodes of head, face, and neck
ICD-10 C82.21 is a billable code used to indicate a diagnosis of follicular lymphoma grade iii, unspecified, lymph nodes of head, face, and neck.
Follicular lymphoma is a type of non-Hodgkin lymphoma characterized by the proliferation of follicle center (germinal center) B-cells. Grade III follicular lymphoma indicates a more aggressive form of the disease, with a higher proliferation index and a greater likelihood of transformation to a more aggressive lymphoma. This specific code pertains to cases where the lymphoma is located in the lymph nodes of the head, face, and neck. Patients may present with painless lymphadenopathy in these regions, and the disease can be associated with B-symptoms such as fever, night sweats, and weight loss. Diagnosis typically involves imaging studies, biopsy, and histological examination to confirm the presence of follicular lymphoma and assess the grade. Treatment options may include watchful waiting, chemotherapy, immunotherapy, or radiation therapy, depending on the stage of the disease and the patient's overall health. The prognosis varies based on the grade and stage at diagnosis, with grade III generally indicating a more aggressive disease course requiring prompt intervention.
Detailed pathology reports, imaging studies, and treatment plans must be documented.
Diagnosis and management of newly diagnosed follicular lymphoma, treatment response evaluation, and management of relapsed disease.
Accurate staging and grading are crucial for treatment planning and prognosis.
Imaging reports must clearly indicate the location and size of lymph nodes involved.
Imaging for staging, follow-up scans to assess treatment response.
Radiologists should be aware of the specific lymph node regions involved in follicular lymphoma.
Used to assess overall health and detect blood disorders in lymphoma patients.
Document the reason for the CBC and any relevant findings.
Hematology specialists should ensure accurate interpretation of CBC results in the context of lymphoma.
Treatment options may include chemotherapy, immunotherapy, and radiation therapy, depending on the stage of the disease and patient health. Clinical trials may also be considered.
